{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T21:02:08Z","timestamp":1764277328522,"version":"3.44.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00761-7","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:24:39Z","timestamp":1748989479000},"page":"1507-1520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing\u2013Remitting Multiple Sclerosis in Italy"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-0223","authenticated-orcid":false,"given":"Barbara","family":"Polistena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"2","key":"761_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"761_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple Sclerosis\u2014a review. Eur J Neurol. 2019;26(1):27\u201340.","journal-title":"Eur J Neurol"},{"key":"761_CR3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the \u201creal MS.\u201d Ther Adv Neurol Disord. 2022;15:1752.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"761_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese M, Preziosa P, Scalfari A, et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol. 2024;96(1):1\u201320.","journal-title":"Ann Neurol"},{"issue":"3","key":"761_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"1","key":"761_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in\u00a0multiple\u00a0sclerosis\u00a0neurotherapeutics. Neurodegener Dis Manag. 2023;13(1):47\u201370.","journal-title":"Neurodegener Dis Manag"},{"issue":"12","key":"761_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380\u201390.","journal-title":"Am J Med"},{"key":"761_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"761_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase\u00a03 trial. Lancet. 2012;380:1829\u201339.","journal-title":"Lancet"},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"761_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, et al. Ofatumumab\u00a0versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"761_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","volume":"16","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271\u201381.","journal-title":"Lancet Neurol"},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1177\/1352458517728812","volume":"24","author":"T Kalincik","year":"2018","unstructured":"Kalincik T, Jokubaitis V, Spelman T, et al. Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis. Mult Scler J. 2018;24:1617\u201326.","journal-title":"Mult Scler J"},{"issue":"4","key":"761_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of\u00a0high efficacy\u00a0therapy\u00a0for\u00a0multiple\u00a0sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:175.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"761_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536\u201341.","journal-title":"JAMA Neurol"},{"issue":"4","key":"761_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14(4):874\u201387. https:\/\/doi.org\/10.1007\/s13311-017-0573-4.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"761_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa0902533.","journal-title":"N Engl J Med"},{"key":"761_CR20","unstructured":"Gazzetta Ufficiale della Repubblica Italiana (GU) n. 65 Serie Generale, 18 marzo 2019."},{"key":"761_CR21","unstructured":"Gazzetta Ufficiale della Repubblica Italiana GU n. 37 Serie Generale, 14 febbraio 2025."},{"key":"761_CR22","unstructured":"Applied Health Economics for Public Health Practice and Research; Ned Hartfiel, Rhiannon T.; chapter 10 \"Cost\u2013consequence analysis of public health interventions\"; 2019 Edwards. https:\/\/academic.oup.com\/book\/24509\/chapter-abstract\/187635547?redirectedFrom=fulltext."},{"key":"761_CR23","unstructured":"\"Barometro della sclerosi multipla e patologie correlate 2023\"; Paolo Bandiera et all.; 2023 (Associazione Italiana Sclerosi Multipla APS\/ETS (AISM), 2023). https:\/\/www.aism.it\/sites\/default\/files\/2023-10\/barometro_2023_web.pdf."},{"key":"761_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458517708176","volume":"23","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, Kobelt G, Ponzio M, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23:104\u201316. https:\/\/doi.org\/10.1177\/1352458517708176.","journal-title":"Mult Scler"},{"key":"761_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21:676\u201386. https:\/\/doi.org\/10.1080\/13696998.2018.1461630.","journal-title":"J Med Econ"},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.vhri.2021.03.007","volume":"25","author":"S Bohlega","year":"2021","unstructured":"Bohlega S, Elboghdady A, Al-Johani A, et al. Economic evaluation of cladribine tablets in patients with high disease activity-relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia. Value Health Reg Issues. 2021;25:189\u201395. https:\/\/doi.org\/10.1016\/j.vhri.2021.03.007.","journal-title":"Value Health Reg Issues"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.18502\/cjn.v20i3.7690","volume":"20","author":"N Ayati","year":"2021","unstructured":"Ayati N, Fleifel L, Sharifi S, Sahraian MA, Nikfar S. Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran. Curr J Neurol. 2021;20:146\u201353. https:\/\/doi.org\/10.18502\/cjn.v20i3.7690.","journal-title":"Curr J Neurol"},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40258-019-00500-8","volume":"17","author":"RE Michels","year":"2019","unstructured":"Michels RE, de Fransesco M, Mahajan K, et al. Cost effectiveness of cladribine tablets for the treatment of relapsing-remitting multiple sclerosis in the Netherlands. Appl Health Econ Health Policy. 2019;17:857\u201373. https:\/\/doi.org\/10.1007\/s40258-019-00500-8.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"761_CR30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14764","volume":"13","author":"G Vivekanandan","year":"2021","unstructured":"Vivekanandan G, Abubacker AP, Myneni R, et al. Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review. Cureus. 2021;13(4):e14764. https:\/\/doi.org\/10.7759\/cureus.14764.","journal-title":"Cureus"},{"issue":"12","key":"761_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197\u2013205. https:\/\/doi.org\/10.1212\/WNL.0000000000003739.","journal-title":"Neurology"},{"key":"761_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/DNND.S203405","volume":"9","author":"M Kartau","year":"2019","unstructured":"Kartau M, Sipil\u00e4 JO, Auvinen E, Palom\u00e4ki M, Verkkoniemi-Ahola A. Progressive multifocal leukoencephalopathy: current insights. Degener Neurol Neuromuscul Dis. 2019;9:109\u201321. https:\/\/doi.org\/10.2147\/DNND.S203405.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"20","key":"761_CR33","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000005529.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00761-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:29:19Z","timestamp":1757179759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00761-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00761-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Maria Provenzano and Caterina Rizzi are employees of Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA. Barbara Polistena received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Eli Lilly, Janssen Cilag, Nestl\u00e9 HS, Novartis, Novo Nordisk, Pfizer, Servier, Takeda, Teva; in addition she received consulting fees from UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data used in the study were from the literature or expert opinion. This study uses a pharmacoeconomic model and therefore the approval of an ethics committee is not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Roberto Bergamaschi has received funding for travel, speaker honoraria, research support from Biogen, Bristol Myers, Janssen, Merck, Novartis, Roche, Sanofi. Elena Colombo reports travel expenses, speaker honoraria, advisory board work and research support from Sanofi, Biogen, Novartis, Merck, Roche, Bristol MS, Janssen, Alexion. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}